(Q33383385)

26 July 2017

title

Cetuximab, topotecan and cisplatin for the treatment of advanced cervical cancer: A phase II GINECO trial (English)

1 reference

26 July 2017

main subject

phase II clinical trial

0 references

1 reference

1 reference

cervix uterine cancer

1 reference

S Lavau-Denes

4

0 references

author name string

J E Kurtz

1

1 reference

26 July 2017

A-C Hardy-Bessard

2

1 reference

26 July 2017

M Deslandres

3

1 reference

26 July 2017

R Largillier

5

1 reference

26 July 2017

C Roemer-Becuwe

6

1 reference

26 July 2017

B Weber

7

1 reference

26 July 2017

C Guillemet

8

1 reference

26 July 2017

D Paraiso

9

1 reference

26 July 2017

E Pujade-Lauraine

10

1 reference

26 July 2017

language of work or name

English

0 references

publication date

15 February 2009

1 reference

26 July 2017

1 reference

26 July 2017

volume

113

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

16-20

1 reference

Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group Study

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.040

Growth factor receptor tyrosine kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.040

Prognostic value of epidermal growth factor receptor expression in cervical carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.040

Expression of epidermal growth factor receptor in carcinoma of the cervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.040

Epidermal growth factor receptor (EGFR) is not related to the prognosis of cervical cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.040

Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.040

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.040

Open-Label, Uncontrolled, Multicenter Phase II Study to Evaluate the Efficacy and Toxicity of Cetuximab As a Single Agent in Patients With Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck Who Failed to Respond to Platinum-Base

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.040

Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.040

Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.040

Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.040

Platinum-based chemotherapy plus cetuximab in head and neck cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2008.12.040

10.1016/J.YGYNO.2008.12.040

7 January 2021

Identifiers

DOI

1 reference

26 July 2017

1 reference